

FY1819 Q4 Performance in Initiating

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Participant Recruited	Reasons for delay correspond to:
18/LO/0538	236451	Evaluating the feasibility and acceptability of a novel mobile intervention targeting social cognition in individuals with psychosis.	26/02/2018	30/04/2018	07/06/2018	03/07/2018	03/07/2018	03/07/2018	43343	Sponsor
18/LO/0128	240068	A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic (Aripiprazole, Olanzapine, Quetiapine, or Risperidone)	18/04/2018	20/04/2018	12/03/2018	04/06/2018	07/06/2018	08/06/2018	12/07/2018	Neither
18/LO/0684	238377	Can imagination change upsetting memories of trauma?	22/03/2018	23/05/2018	23/05/2018	04/07/2018	04/07/2018	04/07/2018	13/08/2018	NHS Provider
18/LO/0362	238744	The Early Youth Engagement in first episode psychosis (EYE-2) study: pragmatic cluster randomised controlled trial of implementation, effectiveness & cost effectiveness of a team-based motivational engagement intervention to improve engagement	14/05/2018	14/05/2018	11/05/2018	08/08/2018	08/08/2018	26/10/2018	09/08/2018	Sponsor
18/LO/1013	244997	Craving Induction and Imagery-based Coping for Cocaine Use Disorder: Clinical Study	16/05/2018	30/07/2018	30/07/2018	10/09/2018	10/09/2018	10/09/2018	14/11/2018	Both
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	29/08/2018	17/08/2018	28/11/2017	21/08/2018	29/08/2018	29/08/2018	N/A	Neither
18/WA/0088	229419	A Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type.	25/04/2018	19/07/2018	26/04/2018	27/07/2018	02/08/2018	07/08/2018	18/01/2019	Neither
18/LO/0575	213457	A Validation Study of a computerized, Artificial Intelligence assisted cognitive assessment test compared to a widely used cognitive assessment test and specialist clinical diagnosis in patients with Alzheimer's Dementia and Mild Cognitive Impairment	15/06/2018	28/08/2018	16/05/2018	31/08/2018	04/09/2018	05/09/2018	25/09/2018	N/A

18/EE/0151	244573	A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies (DELPHIA)	24/07/2018	19/09/2018	31/07/2018	19/09/2018	03/10/2018	03/10/2018	N/A	Neither
18/LO/0287	235360	The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)	24/07/2018	25/07/2018	04/04/2018	03/08/2018	02/08/2018	31/08/2018	N/A	NHS Provider
18/LO/1001	246304	A Global PRospective, Multi-cEnter, ObServational post-markeT Study tO assess shoRt, mid and long-term Effectiveness and efficiency of VNS Therapy® as adjunctive therapy in reaL-world patlents with diFFicult to treat dEpression.	14/05/2018	04/09/2018	13/06/2018	05/09/2018	12/09/2018	13/09/2018	12/10/2018	N/A
18/LO/0731	246135	The Effects of Psilocybin on Cognitive Function in Healthy Participants	24/07/2018	25/07/2018	09/07/2018	03/08/2018	02/08/2018	06/08/2018	17/08/2018	N/A
18/LO/1722	249936	Telephone delivered Incentives for Encouraging adherence to Supervised methadone consumption: a feasibility study for a RCT of clinical and cost effectiveness (TIES)	05/09/2018	11/10/2018	12/11/2018	17/12/2018	17/12/2018	17/12/2018	43479	NHS Provider
18/LO/1683	241656	A randomised controlled feasibility study of food related computerised attention training for obesity versus active (mindfulness-based intervention MBI) and waiting list control (FOCUS)	04/09/2018	13/11/2018	13/11/2018	10/01/2019	10/01/2019	11/02/2019	43544	Both
18/EM/0335	240188	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents with Autism Spectrum Disorders.	23/05/2018	12/11/2018					N/A	Neither
18/NW/0648	244170	ICARUS: An Investigation of Approach Bias Modification Training and Transcranial Direct Current Stimulation in Binge Eating Disorder	28/08/2018	07/11/2018	07/11/2018	12/03/2019	12/03/2019	12/03/2019	43539	Sponsor
18/LO/1634	244432	A pilot randomised controlled trial of Mindfulness Based Cognitive Therapy compared to Psychoeducation in adults with Attention-Deficit/Hyperactivity Disorder	29/08/2018	28/11/2018	28/11/2018	04/01/2019	04/01/2019	04/02/2019	43517	Neither
18/WS/0040	204214	A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia.	13/11/2018	11/12/2018	19/04/2018	12/12/2018	18/12/2018	19/12/2018	11/01/2019	N/A
18/LO/1890	245166	Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: The R-LiNK initiative	19/10/2018	09/01/2019	09/01/2019				N/A	Sponsor
18/LO/02130	243427	Education and Employment focused Individual Placement and Support (IPS) within Early Intervention for Psychosis services: a feasibility study.	09/11/2018	18/01/2019	18/01/2019	02/04/2019	02/04/2019	02/04/2019	N/A	Sponsor

19/LO/0199	256260	Internet-delivered Cognitive Therapy (iCT) for young people with Post-Traumatic Stress Disorder (PTSD): a development case series	04/01/2019	19/03/2019					N/A	N/A
18/SC/0433	249835	A Phase I, randomized, placebo-controlled, open-label, three period crossover study to investigate the effect of darolutamide and enzalutamide on cerebral blood flow in healthy male volunteers.	10/09/2018	28/09/2018	43362	43382	43389	43390	43397	N/A
18/EM/0061	242931	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness	15/05/2018	24/09/2018	01/05/2018	43382	43390	43391	N/A	Neither
18/NE/0248	246929	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION	03/01/2019	21/03/2019	26/09/2018	22/03/2019	02/04/2019	05/04/2019	N/A	N/A